Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Selumetinib controlled recurrent low-grade serous ovarian cancer

AACR 2012

31 Mar - 4 Apr 2012

Published: 13 Apr 2012

Views: 4625

Rating:

Save

Dr John Farley - Creighton University, Phoenix, Arizona, USA

Selumetinib, a small-molecule MEK inhibitor, demonstrated the ability to control low-grade serous ovarian or peritoneal cancer, according to phase II study results presented at a press conference at the AACR Annual Meeting 2012.

ecancerNews Coverage: Selumetinib controlled recurrent low-grade serous ovarian cancer

Related Videos

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial...

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa

Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe

The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa ( Dr Ntokozo Ndlovu - University of Zimbabwe, Harare, Zimbabwe )

Low-dose olanzapine after highly emetogenic chemotherapy can be the new...

Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India

Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours ( Dr Jyoti Bajpai - Tata Memorial Centre, Mumbai, India )

First-line chemotherapy with atezolizumab and bevacizumab significantly...

Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain

First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer ( Dr Ana Oaknin - Vall d´Hebron Institute of Oncology, Barcelona, Spain )

Atezolizumab with platinum-based CT and niraparib show no improvement in...

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

Dostarlimab chemo combination for primary advanced or recurrent endometrial...

Prof Matthew Powell - Washington University School of Medicine, Missouri, USA

Dostarlimab chemo combination for primary advanced or recurrent endometrial cancer ( Prof Matthew Powell - Washington University School of Medicine, Missouri, USA )

More from ecancer